Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DELILAH: Switch to Doravirine/Islatravir vs. Continued ART on Biomarkers of Aging in HIV
NCT07871552Phase 2Not yet recruiting
- Sponsor
- UTHealth Houston
- Start
- Oct 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
A Phase 2 trial of doravirine, islatravir in human immunodeficiency virus infection (HIV), sponsored by UTHealth Houston. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
doravirineislatravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07871552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07871552.